Anticancer agent 330

Anticancer agent 330 (Compound 8) (72 h) exhibits cytotoxic activity comparable to that of Salinomycin (HY-15597) in the A2780, Caov3, OVCAR3, SKOV3 ovarian cancer cell lines and MRC-5 pd19 fibroblasts, and shows improved selectivity towards A2780 and OVCAR3 cells compared with Salinomycin^[1].
Combination treatment with anticancer agent 330 (72 h) and Carboplatin (HY-17393) produces nearly additive interactions in A2780, OVCAR3 and SKOV3 ovarian cancer cell lines, induces moderate antagonistic effects in Caov3 ovarian cancer cells, and exerts differential impacts on cell viability across different cell lines^[1].
Anticancer agent 330 (72 h) regulates the expression of apoptosis- and cell cycle-related proteins in a cell line-dependent manner in A2780, Caov3, OVCAR3 and SKOV3 ovarian cancer cell lines, and its effects when used alone or in combination with Carboplatin are similar to those of Salinomycin^[1].
Anticancer agent 330 regulates ROS production and disrupts mitochondrial membrane potential in a cell line-dependent manner, and this effect involves the A2780, Caov3, OVCAR3 and SKOV3 ovarian cancer cell lines; its efficacy when used alone or in combination with Carboplatin is similar to that of Salinomycin^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.